Dymista is indicated for the symptomatic treatment of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocortocoid is not considered sufficient.
GP and allergy expert Dr Dermot Ryan said it is a challenge for both healthcare professionals and patients to effectively manage hay fever.
"Non-adherence to treatment remains a significant issue, with patients unsure whether current first-line treatments are taking effect, based on their relatively slow onset of action and limited relief of symptoms," Dr Ryan added.
"The introduction of new treatments such as Dymista that can address these issues is an important development in improving the management of such a common, but difficult to manage condition."
Subsequent to European Medicines Agency (EMA) approval, the UK license for the treatment has been obtained.